Clinical Trial

A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Name: A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus — clinical trial record (NCT07082114)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin.

Trial Details

NCT Number	NCT07082114
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions	Type 2 Diabetes
Enrollment	800 participants
Start Date	2025-07-14
Primary Completion	2027-02-16 (estimated)
Study Completion	2027-05-17 (estimated)
Updated on ClinicalTrials.gov	2025-07-24